Organisation paid for research Program year 2025 Source: CMS Open Payments

Consano Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$15,567,906

640 payments

Through program year 2025, Consano Clinical Research LLC is reported as receiving $15,567,906 in research payments, across 640 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,418,730 176
2024 Research $2,528,836 72
2023 Research $2,494,783 82
2022 Research $1,885,552 82
2021 Research $2,423,750 93
2020 Research $1,539,687 62
2019 Research $1,276,568 73

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $12,322,890 238 payments
  2. AstraZeneca Pharmaceuticals LP $782,760 11 payments
  3. Pfizer Inc. $541,958 73 payments
  4. Regeneron Pharmaceuticals, Inc. $516,489 78 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $294,511 18 payments
  6. AbbVie, Inc. $277,779 53 payments
  7. Sanofi US Services Inc. $203,242 21 payments
  8. Genentech, Inc. $155,359 29 payments
  9. Novartis Pharmaceuticals Corporation $139,587 10 payments
  10. Novo Nordisk AS $113,743 27 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $827,892 4 payments
  2. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $753,301 4 payments
  3. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $741,973 4 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $680,695 12 payments
  5. Effectiveness of Once weekly Exenatide (Bcise) Plus Dapagliflozin on 24 Hour Glucose Variability measured by CGM $629,009 3 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $583,573 2 payments
  7. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $583,361 2 payments
  8. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $551,221 4 payments
  9. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus $501,493 4 payments
  10. A Randomized, Phase 3, Open-Label Trial Comparing the Effect of Ly3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes $498,095 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record